Chris Raymond
Stock Analyst at Raymond James
(2.92)
# 1,382
Out of 5,182 analysts
9
Total ratings
66.67%
Success rate
51.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $54.48 | +125.77% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $39.59 | +13.67% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $35.06 | -0.17% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $101.94 | +3.00% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $5.64 | +308.16% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $36.34 | -17.45% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $9.61 | +680.44% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $54.48
Upside: +125.77%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $39.59
Upside: +13.67%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $35.06
Upside: -0.17%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $101.94
Upside: +3.00%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $5.64
Upside: +308.16%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $36.34
Upside: -17.45%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $9.61
Upside: +680.44%